ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells
Metrics: HTML 935 views | ?
Xun Yuan1,2, Dhonghyo Kho2, Jing Xu2, Ambikai Gajan2, Kongming Wu1, Gen Sheng Wu2
1Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, P.R. China
2Departments of Oncology and Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, 48201, USA
Gen Sheng Wu, email: firstname.lastname@example.org
Kongming Wu, email: email@example.com
Keywords: ONC201, triple-negative breast cancer, TRAIL, ATF4, apoptosis
Received: December 20, 2016 Accepted: January 24, 2017 Published: February 17, 2017
ONC201 was previously identified as a first-in-class antitumor agent and small-molecule inducer of the TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) gene that induces apoptosis in cancer cells. ONC201 has a safety profile and is currently in phase II clinical trials for the treatment of various malignancies. In the current study, we examine the effect of ONC201 on triple-negative breast cancer cells (TNBC), a subtype of breast cancer that is sensitive to TRAIL. We find that ONC201 inhibits the growth of TNBC cells including TNBC cells that have developed acquired TRAIL resistance. However, TNBC cells that have developed acquired ONC201 resistance are cross-resistant to TRAIL. Mechanistically, ONC201 triggers an integrated stress response (ISR) involving the activation of the transcription factor ATF4. Knockdown of ATF4 impairs ONC201-induced apoptosis of TNBC cells. Importantly, the activation of ATF4 is compromised in ONC201-resistant TNBC cells. Thus, our results indicate that ONC201 induces an ISR to cause TNBC cell death and suggest that TNBC patients may benefit from ONC201-based therapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.